The European Medicines Agency has granted priority medicines and advanced therapy medicinal product designations for AAV-RPGR, an investigational gene therapy treatment for X-linked retinitis pigmentosa, according to press releases from MeiraGTx Holdings and Janssen Pharmaceuticals, which are jointly developing the therapy.
The therapy is the only RPGR gene therapy program to be awarded priority medicines (PRIME) designation, which is given “to increase interactions, optimize development plans and accelerate innovative treatments where there is unmet medical need,” according to the
Uncategorized